Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA
Breast Cancer Research and Treatment · 2025
DOI: 10.1007/s10549-025-07705-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2025. Verfasst von Neelima Vidula und 4 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts General Hospital Cancer Center, Boston, MA, 02114, USA. nvidula@mgh.harvard.edu. Hauptthemen laut MEDLINE: Breast Neoplasms, BRCA2 Protein, Brain Neoplasms, BRCA1 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Brain metastases (BM) in patients with metastatic breast cancer (MBC) cause significant morbidity/mortality. A relatively high prevalence of BM is seen in patients with germline BRCA1/2 mutations. Some patients with MBC have somatic BRCA1/2 mutations but the prevalence of BM in this setting is not known. METHODS: Here, we evaluated the prevalence and clinical and genomic characteristics of BM in patients with MBC with somatic BRCA1/2 mutations in cell-free DNA (cfDNA) using the Guardant360 assay. Clinical and genomic features of patients with somatic BRCA1/2 mutations and brain metastases, and those without brain metastases were compared using a Chi-squared test for categorical variables and Wilcoxon rank-sum test for continuous variables. RESULTS: Of 36 patients with MBC and somatic BRCA1/2 mutations, 9 (25%) developed BM. The median time to development of BM was 6.7 months after somatic BRCA detection by cfDNA testing. Among patients with BM, somatic BRCA mutations were commonly BRCA1, clonal, and present at a higher mutant allelic fraction. The coexisting genomic landscape in patients with BM commonly included PIK3CA, TP53, MYC, EGFR, CCNE1, and KIT mutations. CONCLUSION: A relatively high prevalence of BM in patients with MBC harboring cfDNA somatic BRCA1/2 mutations was observed. CfDNA somatic BRCA1/2 mutations may help identify patients with MBC at risk for BM. To our knowledge, this is the first report linking cfDNA somatic BRCA mutations with BM, and requires further investigation in additional datasets and studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Massachusetts General Hospital Cancer Center, Boston, MA, 02114, USA. nvidula@mgh.harvard.edu.
- Massachusetts General Hospital Cancer Center, Boston, MA, 02114, USA.
- University of California Los Angeles, Los Angeles, CA, USA.
Zitieren
APA
Vidula, N., Blouch, E., Hesler, K., Niemierko, A., & Bardia, A. (2025). Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-025-07705-7
Vancouver
Vidula N, Blouch E, Hesler K, Niemierko A, Bardia A. Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA. Breast Cancer Research and Treatment. 2025. doi:10.1007/s10549-025-07705-7
BibTeX
@article{Vidula2025,
author = {Vidula, Neelima and Blouch, Erica and Hesler, Katherine and Niemierko, Andrzej and Bardia, Aditya},
title = {Brain metastases in patients with metastatic breast cancer and BRCA1/2 mutations in cell-free DNA},
journal = {Breast Cancer Research and Treatment},
year = {2025},
doi = {10.1007/s10549-025-07705-7}
}
EUVIMED